Quantification	O
of	O
apigenin	B:C0533187
trimethyl	I:C0533187
ether	I:C0533187
in	O
rat	O
plasma	O
by	O
liquid	O
chromatography	I:C4049918
-	I:C4049918
tandem	I:C4049918
mass	I:C4049918
spectrometry	I:C4049918
:	O
Application	O
to	O
a	O
pre-clinical	O
pharmacokinetic	O
study	I:C0201734
Apigenin	O
trimethyl	I:C0533187
ether	I:C0533187
(	O
5,7,4	O
'	I:C0533187
-	I:C0533187
trimethoxyflavone	I:C0533187
,	O
ATE	O
)	O
is	O
a	O
naturally	O
occurring	O
polymethoxyflavone	O
with	O
a	O
wide	O
range	O
of	O
health	O
-	I:C0517496
promoting	I:C0517496
activities	I:C0517496
.	O

Quantification	O
of	O
apigenin	O
trimethyl	I:C0533187
ether	I:C0533187
in	O
rat	B:C0034721
plasma	O
by	O
liquid	O
chromatography	I:C4049918
-	I:C4049918
tandem	I:C4049918
mass	I:C4049918
spectrometry	I:C4049918
:	O
Application	O
to	O
a	O
pre-clinical	O
pharmacokinetic	O
study	I:C0201734
Apigenin	O
trimethyl	I:C0533187
ether	I:C0533187
(	O
5,7,4	O
'	I:C0533187
-	I:C0533187
trimethoxyflavone	I:C0533187
,	O
ATE	O
)	O
is	O
a	O
naturally	O
occurring	O
polymethoxyflavone	O
with	O
a	O
wide	O
range	O
of	O
health	O
-	I:C0517496
promoting	I:C0517496
activities	I:C0517496
.	O

Quantification	O
of	O
apigenin	O
trimethyl	I:C0533187
ether	I:C0533187
in	O
rat	O
plasma	B:C0032105
by	O
liquid	O
chromatography	I:C4049918
-	I:C4049918
tandem	I:C4049918
mass	I:C4049918
spectrometry	I:C4049918
:	O
Application	O
to	O
a	O
pre-clinical	O
pharmacokinetic	O
study	I:C0201734
Apigenin	O
trimethyl	I:C0533187
ether	I:C0533187
(	O
5,7,4	O
'	I:C0533187
-	I:C0533187
trimethoxyflavone	I:C0533187
,	O
ATE	O
)	O
is	O
a	O
naturally	O
occurring	O
polymethoxyflavone	O
with	O
a	O
wide	O
range	O
of	O
health	O
-	I:C0517496
promoting	I:C0517496
activities	I:C0517496
.	O

Quantification	O
of	O
apigenin	O
trimethyl	I:C0533187
ether	I:C0533187
in	O
rat	O
plasma	O
by	O
liquid	B:C4049918
chromatography	I:C4049918
-	I:C4049918
tandem	I:C4049918
mass	I:C4049918
spectrometry	I:C4049918
:	O
Application	O
to	O
a	O
pre-clinical	O
pharmacokinetic	O
study	I:C0201734
Apigenin	O
trimethyl	I:C0533187
ether	I:C0533187
(	O
5,7,4	O
'	I:C0533187
-	I:C0533187
trimethoxyflavone	I:C0533187
,	O
ATE	O
)	O
is	O
a	O
naturally	O
occurring	O
polymethoxyflavone	O
with	O
a	O
wide	O
range	O
of	O
health	O
-	I:C0517496
promoting	I:C0517496
activities	I:C0517496
.	O

Quantification	O
of	O
apigenin	O
trimethyl	I:C0533187
ether	I:C0533187
in	O
rat	O
plasma	O
by	O
liquid	O
chromatography	I:C4049918
-	I:C4049918
tandem	I:C4049918
mass	I:C4049918
spectrometry	I:C4049918
:	O
Application	O
to	O
a	O
pre-clinical	O
pharmacokinetic	B:C0201734
study	I:C0201734
Apigenin	O
trimethyl	I:C0533187
ether	I:C0533187
(	O
5,7,4	O
'	I:C0533187
-	I:C0533187
trimethoxyflavone	I:C0533187
,	O
ATE	O
)	O
is	O
a	O
naturally	O
occurring	O
polymethoxyflavone	O
with	O
a	O
wide	O
range	O
of	O
health	O
-	I:C0517496
promoting	I:C0517496
activities	I:C0517496
.	O

Quantification	O
of	O
apigenin	O
trimethyl	I:C0533187
ether	I:C0533187
in	O
rat	O
plasma	O
by	O
liquid	O
chromatography	I:C4049918
-	I:C4049918
tandem	I:C4049918
mass	I:C4049918
spectrometry	I:C4049918
:	O
Application	O
to	O
a	O
pre-clinical	O
pharmacokinetic	O
study	I:C0201734
Apigenin	B:C0533187
trimethyl	I:C0533187
ether	I:C0533187
(	O
5,7,4	O
'	I:C0533187
-	I:C0533187
trimethoxyflavone	I:C0533187
,	O
ATE	O
)	O
is	O
a	O
naturally	O
occurring	O
polymethoxyflavone	O
with	O
a	O
wide	O
range	O
of	O
health	O
-	I:C0517496
promoting	I:C0517496
activities	I:C0517496
.	O

Quantification	O
of	O
apigenin	O
trimethyl	I:C0533187
ether	I:C0533187
in	O
rat	O
plasma	O
by	O
liquid	O
chromatography	I:C4049918
-	I:C4049918
tandem	I:C4049918
mass	I:C4049918
spectrometry	I:C4049918
:	O
Application	O
to	O
a	O
pre-clinical	O
pharmacokinetic	O
study	I:C0201734
Apigenin	O
trimethyl	I:C0533187
ether	I:C0533187
(	O
5,7,4	B:C0533187
'	I:C0533187
-	I:C0533187
trimethoxyflavone	I:C0533187
,	O
ATE	O
)	O
is	O
a	O
naturally	O
occurring	O
polymethoxyflavone	O
with	O
a	O
wide	O
range	O
of	O
health	O
-	I:C0517496
promoting	I:C0517496
activities	I:C0517496
.	O

Quantification	O
of	O
apigenin	O
trimethyl	I:C0533187
ether	I:C0533187
in	O
rat	O
plasma	O
by	O
liquid	O
chromatography	I:C4049918
-	I:C4049918
tandem	I:C4049918
mass	I:C4049918
spectrometry	I:C4049918
:	O
Application	O
to	O
a	O
pre-clinical	O
pharmacokinetic	O
study	I:C0201734
Apigenin	O
trimethyl	I:C0533187
ether	I:C0533187
(	O
5,7,4	O
'	I:C0533187
-	I:C0533187
trimethoxyflavone	I:C0533187
,	O
ATE	B:C0533187
)	O
is	O
a	O
naturally	O
occurring	O
polymethoxyflavone	O
with	O
a	O
wide	O
range	O
of	O
health	O
-	I:C0517496
promoting	I:C0517496
activities	I:C0517496
.	O

Quantification	O
of	O
apigenin	O
trimethyl	I:C0533187
ether	I:C0533187
in	O
rat	O
plasma	O
by	O
liquid	O
chromatography	I:C4049918
-	I:C4049918
tandem	I:C4049918
mass	I:C4049918
spectrometry	I:C4049918
:	O
Application	O
to	O
a	O
pre-clinical	O
pharmacokinetic	O
study	I:C0201734
Apigenin	O
trimethyl	I:C0533187
ether	I:C0533187
(	O
5,7,4	O
'	I:C0533187
-	I:C0533187
trimethoxyflavone	I:C0533187
,	O
ATE	O
)	O
is	O
a	O
naturally	O
occurring	O
polymethoxyflavone	B:C0016219
with	O
a	O
wide	O
range	O
of	O
health	O
-	I:C0517496
promoting	I:C0517496
activities	I:C0517496
.	O

Quantification	O
of	O
apigenin	O
trimethyl	I:C0533187
ether	I:C0533187
in	O
rat	O
plasma	O
by	O
liquid	O
chromatography	I:C4049918
-	I:C4049918
tandem	I:C4049918
mass	I:C4049918
spectrometry	I:C4049918
:	O
Application	O
to	O
a	O
pre-clinical	O
pharmacokinetic	O
study	I:C0201734
Apigenin	O
trimethyl	I:C0533187
ether	I:C0533187
(	O
5,7,4	O
'	I:C0533187
-	I:C0533187
trimethoxyflavone	I:C0533187
,	O
ATE	O
)	O
is	O
a	O
naturally	O
occurring	O
polymethoxyflavone	O
with	O
a	O
wide	O
range	O
of	O
health	B:C0517496
-	I:C0517496
promoting	I:C0517496
activities	I:C0517496
.	O

In	O
this	O
study	B:C2603343
,	O
a	O
sensitive	O
liquid	O
chromatography	I:C4049918
-	I:C4049918
tandem	I:C4049918
mass	I:C4049918
spectrometry	I:C4049918
(	O
LC	O
-	I:C4049918
MS	I:C4049918
/	I:C4049918
MS	I:C4049918
)	O
method	O
was	O
developed	O
and	O
validated	O
for	O
the	O
quantification	O
of	O
ATE	O
in	O
rat	O
plasma	O
.	O

In	O
this	O
study	O
,	O
a	O
sensitive	O
liquid	B:C4049918
chromatography	I:C4049918
-	I:C4049918
tandem	I:C4049918
mass	I:C4049918
spectrometry	I:C4049918
(	O
LC	O
-	I:C4049918
MS	I:C4049918
/	I:C4049918
MS	I:C4049918
)	O
method	O
was	O
developed	O
and	O
validated	O
for	O
the	O
quantification	O
of	O
ATE	O
in	O
rat	O
plasma	O
.	O

In	O
this	O
study	O
,	O
a	O
sensitive	O
liquid	O
chromatography	I:C4049918
-	I:C4049918
tandem	I:C4049918
mass	I:C4049918
spectrometry	I:C4049918
(	O
LC	B:C4049918
-	I:C4049918
MS	I:C4049918
/	I:C4049918
MS	I:C4049918
)	O
method	O
was	O
developed	O
and	O
validated	O
for	O
the	O
quantification	O
of	O
ATE	O
in	O
rat	O
plasma	O
.	O

In	O
this	O
study	O
,	O
a	O
sensitive	O
liquid	O
chromatography	I:C4049918
-	I:C4049918
tandem	I:C4049918
mass	I:C4049918
spectrometry	I:C4049918
(	O
LC	O
-	I:C4049918
MS	I:C4049918
/	I:C4049918
MS	I:C4049918
)	O
method	B:C0025663
was	O
developed	O
and	O
validated	O
for	O
the	O
quantification	O
of	O
ATE	O
in	O
rat	O
plasma	O
.	O

In	O
this	O
study	O
,	O
a	O
sensitive	O
liquid	O
chromatography	I:C4049918
-	I:C4049918
tandem	I:C4049918
mass	I:C4049918
spectrometry	I:C4049918
(	O
LC	O
-	I:C4049918
MS	I:C4049918
/	I:C4049918
MS	I:C4049918
)	O
method	O
was	O
developed	O
and	O
validated	B:C1519941
for	O
the	O
quantification	O
of	O
ATE	O
in	O
rat	O
plasma	O
.	O

In	O
this	O
study	O
,	O
a	O
sensitive	O
liquid	O
chromatography	I:C4049918
-	I:C4049918
tandem	I:C4049918
mass	I:C4049918
spectrometry	I:C4049918
(	O
LC	O
-	I:C4049918
MS	I:C4049918
/	I:C4049918
MS	I:C4049918
)	O
method	O
was	O
developed	O
and	O
validated	O
for	O
the	O
quantification	O
of	O
ATE	B:C0533187
in	O
rat	O
plasma	O
.	O

In	O
this	O
study	O
,	O
a	O
sensitive	O
liquid	O
chromatography	I:C4049918
-	I:C4049918
tandem	I:C4049918
mass	I:C4049918
spectrometry	I:C4049918
(	O
LC	O
-	I:C4049918
MS	I:C4049918
/	I:C4049918
MS	I:C4049918
)	O
method	O
was	O
developed	O
and	O
validated	O
for	O
the	O
quantification	O
of	O
ATE	O
in	O
rat	B:C0034721
plasma	O
.	O

In	O
this	O
study	O
,	O
a	O
sensitive	O
liquid	O
chromatography	I:C4049918
-	I:C4049918
tandem	I:C4049918
mass	I:C4049918
spectrometry	I:C4049918
(	O
LC	O
-	I:C4049918
MS	I:C4049918
/	I:C4049918
MS	I:C4049918
)	O
method	O
was	O
developed	O
and	O
validated	O
for	O
the	O
quantification	O
of	O
ATE	O
in	O
rat	O
plasma	B:C0032105
.	O

Protein	B:C3815102
precipitation	I:C3815102
was	O
applied	O
as	O
plasma	O
clean	O
-	O
up	O
procedure	O
;	O
the	O
electrospray	O
ionization	I:C1516801
was	O
operated	O
in	O
its	O
positive	O
ion	O
mode	O
while	O
ATE	O
and	O
formononetin	O
(	O
internal	O
standard	O
)	O
were	O
measured	O
by	O
multiple	O
reactions	I:C0025663
monitoring	I:C0025663
(	O
ATE	O
:	O
m/z	O
313.1→298.1	O
;	O
formononetin	O
:	O
269.2→213.3	O
)	O
.	O

Protein	O
precipitation	I:C3815102
was	O
applied	O
as	O
plasma	B:C0032105
clean	O
-	O
up	O
procedure	O
;	O
the	O
electrospray	O
ionization	I:C1516801
was	O
operated	O
in	O
its	O
positive	O
ion	O
mode	O
while	O
ATE	O
and	O
formononetin	O
(	O
internal	O
standard	O
)	O
were	O
measured	O
by	O
multiple	O
reactions	I:C0025663
monitoring	I:C0025663
(	O
ATE	O
:	O
m/z	O
313.1→298.1	O
;	O
formononetin	O
:	O
269.2→213.3	O
)	O
.	O

Protein	O
precipitation	I:C3815102
was	O
applied	O
as	O
plasma	O
clean	O
-	O
up	O
procedure	O
;	O
the	O
electrospray	B:C1516801
ionization	I:C1516801
was	O
operated	O
in	O
its	O
positive	O
ion	O
mode	O
while	O
ATE	O
and	O
formononetin	O
(	O
internal	O
standard	O
)	O
were	O
measured	O
by	O
multiple	O
reactions	I:C0025663
monitoring	I:C0025663
(	O
ATE	O
:	O
m/z	O
313.1→298.1	O
;	O
formononetin	O
:	O
269.2→213.3	O
)	O
.	O

Protein	O
precipitation	I:C3815102
was	O
applied	O
as	O
plasma	O
clean	O
-	O
up	O
procedure	O
;	O
the	O
electrospray	O
ionization	I:C1516801
was	O
operated	O
in	O
its	O
positive	O
ion	O
mode	O
while	O
ATE	B:C0533187
and	O
formononetin	O
(	O
internal	O
standard	O
)	O
were	O
measured	O
by	O
multiple	O
reactions	I:C0025663
monitoring	I:C0025663
(	O
ATE	O
:	O
m/z	O
313.1→298.1	O
;	O
formononetin	O
:	O
269.2→213.3	O
)	O
.	O

Protein	O
precipitation	I:C3815102
was	O
applied	O
as	O
plasma	O
clean	O
-	O
up	O
procedure	O
;	O
the	O
electrospray	O
ionization	I:C1516801
was	O
operated	O
in	O
its	O
positive	O
ion	O
mode	O
while	O
ATE	O
and	O
formononetin	B:C0060656
(	O
internal	O
standard	O
)	O
were	O
measured	O
by	O
multiple	O
reactions	I:C0025663
monitoring	I:C0025663
(	O
ATE	O
:	O
m/z	O
313.1→298.1	O
;	O
formononetin	O
:	O
269.2→213.3	O
)	O
.	O

Protein	O
precipitation	I:C3815102
was	O
applied	O
as	O
plasma	O
clean	O
-	O
up	O
procedure	O
;	O
the	O
electrospray	O
ionization	I:C1516801
was	O
operated	O
in	O
its	O
positive	O
ion	O
mode	O
while	O
ATE	O
and	O
formononetin	O
(	O
internal	O
standard	O
)	O
were	O
measured	O
by	O
multiple	B:C0025663
reactions	I:C0025663
monitoring	I:C0025663
(	O
ATE	O
:	O
m/z	O
313.1→298.1	O
;	O
formononetin	O
:	O
269.2→213.3	O
)	O
.	O

Protein	O
precipitation	I:C3815102
was	O
applied	O
as	O
plasma	O
clean	O
-	O
up	O
procedure	O
;	O
the	O
electrospray	O
ionization	I:C1516801
was	O
operated	O
in	O
its	O
positive	O
ion	O
mode	O
while	O
ATE	O
and	O
formononetin	O
(	O
internal	O
standard	O
)	O
were	O
measured	O
by	O
multiple	O
reactions	I:C0025663
monitoring	I:C0025663
(	O
ATE	B:C0533187
:	O
m/z	O
313.1→298.1	O
;	O
formononetin	O
:	O
269.2→213.3	O
)	O
.	O

Protein	O
precipitation	I:C3815102
was	O
applied	O
as	O
plasma	O
clean	O
-	O
up	O
procedure	O
;	O
the	O
electrospray	O
ionization	I:C1516801
was	O
operated	O
in	O
its	O
positive	O
ion	O
mode	O
while	O
ATE	O
and	O
formononetin	O
(	O
internal	O
standard	O
)	O
were	O
measured	O
by	O
multiple	O
reactions	I:C0025663
monitoring	I:C0025663
(	O
ATE	O
:	O
m/z	O
313.1→298.1	O
;	O
formononetin	B:C0060656
:	O
269.2→213.3	O
)	O
.	O

This	O
LC	B:C4049918
-	I:C4049918
MS	I:C4049918
/	I:C4049918
MS	I:C4049918
method	I:C4049918
displayed	O
good	O
selectivity	O
,	O
sensitivity	O
(	O
lower	O
limit	O
of	O
quantification	O
=	O
2.5ng	O
/	O
ml	O
)	O
,	O
accuracy	O
(	O
both	O
intra	O
-	O
and	O
inter	O
-	O
day	O
analytical	O
recovery	O
within	O
100±10	O
%	O
)	O
and	O
precision	O
(	O
both	O
intra-	O
and	O
inter-day	O
RSD	O
<	O
10	O
%	O
)	O
.	O

The	O
pharmacokinetic	O
profiles	O
of	O
ATE	B:C0533187
were	O
subsequently	O
examined	O
in	O
Sprague	O
-	I:C0034715
Dawley	I:C0034715
rats	I:C0034715
after	O
single	O
oral	O
administration	I:C0001563
(	O
10mg/kg	O
)	O
.	O

The	O
pharmacokinetic	O
profiles	O
of	O
ATE	O
were	O
subsequently	O
examined	B:C0332128
in	O
Sprague	O
-	I:C0034715
Dawley	I:C0034715
rats	I:C0034715
after	O
single	O
oral	O
administration	I:C0001563
(	O
10mg/kg	O
)	O
.	O

The	O
pharmacokinetic	O
profiles	O
of	O
ATE	O
were	O
subsequently	O
examined	O
in	O
Sprague	B:C0034715
-	I:C0034715
Dawley	I:C0034715
rats	I:C0034715
after	O
single	O
oral	O
administration	I:C0001563
(	O
10mg/kg	O
)	O
.	O

The	O
pharmacokinetic	O
profiles	O
of	O
ATE	O
were	O
subsequently	O
examined	O
in	O
Sprague	O
-	I:C0034715
Dawley	I:C0034715
rats	I:C0034715
after	O
single	O
oral	B:C0001563
administration	I:C0001563
(	O
10mg/kg	O
)	O
.	O

When	O
given	O
in	O
an	O
aqueous	B:C0038960
suspension	I:C0038960
,	O
ATE	O
was	O
slowly	O
absorbed	O
with	O
quite	O
low	O
plasma	O
exposure	O
(	O
AUC	O
)	O
.	O

When	O
given	O
in	O
an	O
aqueous	O
suspension	I:C0038960
,	O
ATE	B:C0533187
was	O
slowly	O
absorbed	O
with	O
quite	O
low	O
plasma	O
exposure	O
(	O
AUC	O
)	O
.	O

When	O
given	O
in	O
an	O
aqueous	O
suspension	I:C0038960
,	O
ATE	O
was	O
slowly	O
absorbed	O
with	O
quite	O
low	O
plasma	B:C0032105
exposure	O
(	O
AUC	O
)	O
.	O

Fasting	O
further	O
attenuated	O
its	O
oral	B:C0442027
absorption	O
and	O
led	O
to	O
∼	O
70	O
%	O
drops	O
in	O
average	O
maximal	O
plasma	O
concentration	O
(	O
Cmax	O
)	O
and	O
AUC	O
.	O

When	O
dosed	O
in	O
a	O
solution	O
formulated	B:C0524527
with	O
2	O
-	I:C0046237
hydroxypropyl	I:C0046237
-β-	I:C0046237
cyclodextrin	I:C0046237
,	O
the	O
oral	O
absorption	O
of	O
ATE	O
was	O
substantially	O
improved	I:C0184511
with	O
∼500	O
%	O
increases	O
in	O
average	O
Cmax	O
and	O
AUC	O
.	O

When	O
dosed	O
in	O
a	O
solution	O
formulated	O
with	O
2	B:C0046237
-	I:C0046237
hydroxypropyl	I:C0046237
-β-	I:C0046237
cyclodextrin	I:C0046237
,	O
the	O
oral	O
absorption	O
of	O
ATE	O
was	O
substantially	O
improved	I:C0184511
with	O
∼500	O
%	O
increases	O
in	O
average	O
Cmax	O
and	O
AUC	O
.	O

When	O
dosed	O
in	O
a	O
solution	O
formulated	O
with	O
2	O
-	I:C0046237
hydroxypropyl	I:C0046237
-β-	I:C0046237
cyclodextrin	I:C0046237
,	O
the	O
oral	B:C0442027
absorption	O
of	O
ATE	O
was	O
substantially	O
improved	I:C0184511
with	O
∼500	O
%	O
increases	O
in	O
average	O
Cmax	O
and	O
AUC	O
.	O

When	O
dosed	O
in	O
a	O
solution	O
formulated	O
with	O
2	O
-	I:C0046237
hydroxypropyl	I:C0046237
-β-	I:C0046237
cyclodextrin	I:C0046237
,	O
the	O
oral	O
absorption	O
of	O
ATE	B:C0533187
was	O
substantially	O
improved	I:C0184511
with	O
∼500	O
%	O
increases	O
in	O
average	O
Cmax	O
and	O
AUC	O
.	O

When	O
dosed	O
in	O
a	O
solution	O
formulated	O
with	O
2	O
-	I:C0046237
hydroxypropyl	I:C0046237
-β-	I:C0046237
cyclodextrin	I:C0046237
,	O
the	O
oral	O
absorption	O
of	O
ATE	O
was	O
substantially	B:C0184511
improved	I:C0184511
with	O
∼500	O
%	O
increases	O
in	O
average	O
Cmax	O
and	O
AUC	O
.	O

Clearly	O
,	O
aqueous	O
solubility	O
has	O
been	O
identified	O
as	O
a	O
barrier	O
to	O
the	O
oral	B:C0442027
absorption	O
of	O
ATE	O
.	O

Clearly	O
,	O
aqueous	O
solubility	O
has	O
been	O
identified	O
as	O
a	O
barrier	O
to	O
the	O
oral	O
absorption	O
of	O
ATE	B:C0533187
.	O

The	O
information	O
obtained	O
from	O
this	O
study	B:C2603343
will	O
facilitate	O
further	O
medicinal	O
exploration	O
on	O
ATE	O
.	O

The	O
information	O
obtained	O
from	O
this	O
study	O
will	O
facilitate	O
further	O
medicinal	B:C0013227
exploration	O
on	O
ATE	O
.	O

The	O
information	O
obtained	O
from	O
this	O
study	O
will	O
facilitate	O
further	O
medicinal	O
exploration	B:C3494260
on	O
ATE	O
.	O

The	O
information	O
obtained	O
from	O
this	O
study	O
will	O
facilitate	O
further	O
medicinal	O
exploration	O
on	O
ATE	B:C0533187
.	O

